Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: Jefferson Research
Provider: Directors Deals Ltd.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc reaffirms FY 2013 guidance

Wednesday, 11 Dec 2013 06:40pm EST 

Emergent BioSolutions Inc:Says reaffirmed FY 2013 GAAP guidance for total revenues of $300 to $310 million and net income of $25 to $30 million.Says excluding about $7 million in estimated transaction-related and other costs incurred in the current year, the company is providing a forecast for FY 2013 non-GAAP adjusted net income of $30 to $35 million.FY 2013 revenue of $308 mln and net income of $30 mln - Thomson Reuters I/B/E/S Estimates. 

Related Company News

Company Quote

0.07 +0.26%
19 Dec 2014